ClinicalTrials.gg
CompletedNCT03112603Updated Aug 12, 2025Results posted

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

A Phase 3 interventional study of Ruxolitinib and Extracorporeal photopheresis (ECP) in Graft-versus-host Disease (GVHD), sponsored by Incyte Corporation. Completed at 191 sites in 31 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-12.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing ruxolitinib in Graft vs Host Disease — 13 open to participants now, 16 under way, 2 of them phase 3. ruxolitinib · Graft vs Host Disease.

Enrollment
3rd of 27
330 · median 54
Started
2017
with 1 other
Phase 3
3 of 27
1 open now
Registered
5th of 27
by date
Lead sponsor
3 of 27
Incyte Corporation

Among the 27 studies testing ruxolitinib in Graft vs Host Disease, this one is the 3rd largest by enrollment, is one of 2 that started in 2017, is one of 3 in phase 3, and was the 5th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

13 of the 27 studies testing ruxolitinib in Graft vs Host Disease are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing ruxolitinib in Graft vs Host Disease, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of ruxolitinib against best available therapy in participants with steroid-refractory chronic graft-versus-host disease (SR cGvHD).

03

Conditions studied

  • Graft-versus-host Disease (GVHD)

Keywords

  • Graft-versus-host disease (GvHD)
  • Chronic GvHD (cGvHD)
  • steroid-refractory
  • ruxolitinib
  • Janus kinase inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have undergone stem cell transplantation (alloSCT) from any donor source (matched unrelated donor, sibling, haplo-identical) using bone marrow, peripheral blood stem cells, or cord blood. Recipients of non-myeloablative, myeloablative, and reduced intensity conditioning are eligible
  • Evident myeloid and engraftment: (ANC) > 1000/mm\^3 and platelet count > 25,000/ mm\^3
  • Participants with clinically diagnosed moderate to severe cGvHD according to NIH Consensus Criteria prior to randomization:

    • Moderate cGvHD: At least one organ (not lung) with a score of 2, 3 or more organs involved with a score of 1 in each organ, or lung score of 1
    • Severe cGvHD: at least 1 organ with a score of 3, or lung score of 2 or 3
  • Participants currently receiving systemic or topical for the treatment of cGvHD for a duration of \< 12 months prior to Cycle 1 Day 1 (if applicable), and have a confirmed diagnosis of steroid- cGvHD defined per 2014 NIH consensus criteria irrespective of the concomitant use of a calcineurin inhibitor (CNI), as follows:

    • A lack of response or disease progression after administration of minimum prednisone 1 mg/kg/day for at least 1 week, OR
    • Disease persistence without improvement despite continued treatment with prednisone at > 0.5 mg/kg/day or 1 mg/kg/every other day for at least 4 weeks, OR
    • Increase to prednisolone dose to > 0.25 mg/kg/day after 2 unsuccessful attempts to taper the dose
  • Participant must accept to be treated with only one of the following BAT options on Cycle 1 Day 1 (additions and changes are allowed during the course of the study, but only with BAT from the following BAT options): extracorporeal photopheresis (ECP), low-dose methotrexate (MTX), mycophenolate mofetil (MMF), mTOR inhibitors (everolimus or sirolimus), infliximab, rituximab, pentostatin, imatinib, ibrutinib

Exclusion criteria

Exclusion Criteria:

  • Participants who have received 2 or more systemic treatment for cGvHD in addition to ± CNI for cGvHD
  • Patients that transition from active aGvHD to cGvHD without tapering off corticosteroids ± CNI and any systemic treatment

    * Patients receiving up to 30 mg by mouth once a day of hydrocortisone (i.e., physiologic replacement dose) of corticosteroids are allowed.

  • Participants who were treated with prior JAK inhibitors for aGvHD; except when the participant achieved complete or partial response and has been off JAK inhibitor treatment for at least 8 weeks prior to Cycle 1 Day 1
  • Failed prior alloSCT within the past 6 months from Cycle 1 Day 1
  • Participants with primary , or who have been treated for relapse after the alloSCT was performed
  • Steroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligible
  • Any corticosteroid therapy for indications other than cGvHD at doses > 1 mg/kg/day methylprednisolone or equivalent within 7 days of Cycle 1 Day 1
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Ruxolitinib

    Ruxolitinib for the treatment period and extension period.

    Drug: Ruxolitinib

  • Active comparator
    Best Available Therapy

    Best available therapy for the treatment period and extension period, with optional crossover to ruxolitinib after Cycle 6.

    Drug: Extracorporeal photopheresis (ECP) · Drug: Low-dose methotrexate (MTX) · Drug: Mycophenolate mofetil (MMF) · Drug: mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) · Drug: Infliximab · Drug: Rituximab · Drug: Pentostatin · Drug: Imatinib · Drug: Ibrutinib

Interventions

  • Ruxolitinib twice daily at the protocol-defined starting dose.

    Also known as: Jakafi, INCB018424

  • DrugExtracorporeal photopheresis (ECP)

    Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Drugmechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)

    Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

  • Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.

06

What researchers measure

Primary outcomes

  1. Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit

    ORR was defined as the percentage of participants in each arm demonstrating a complete response (CR) or partial response (PR) based on chronic GvHD (cGvHD) disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

    Time frame: Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

Secondary outcomes

  1. Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score

    To assess improvement of symptoms based on the total symptom score (TSS); a responder was defined as having achieved a clinically relevant reduction from Baseline of the TSS. The scale consists of 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological). Participants reported their level of symptom "bother" over the previous month on a 5-point likert scale: not at all, slightly, moderately, quite a bit, or extremely. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.

    Time frame: Baseline; Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

  2. Rate of Failure-free Survival (FFS)

    Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.

    Time frame: Baseline to when the last participant reached Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

  3. Rate of FFS at Study Completion

    Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.

    Time frame: From Baseline to Last Participant Last Visit (LPLV) (approximately 5 years)

  4. Best Overall Response (BOR) at Cycle 7 Day 1

    BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies. This analysis was based on the primary cutoff date (May 2020).

    Time frame: up to Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

  5. BOR During Cross-over Treatment With Ruxolitinib

    BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

    Time frame: from Crossover Cycle 1 Day 1 to any time point up to and including Crossover Cycle 7 Day 1 (each cycle was comprised of 4 weeks)

  6. ORR at the End of Cycle 3

    ORR was defined as the percentage of participants in each arm demonstrating a CR or PR based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

    Time frame: Cycle 4 Day 1 (each cycle was comprised of 4 weeks)

  7. Duration of Response Through Study Completion

    DOR was defined as the time from first response until cGvHD progression, death, or the date of change/addition of systemic therapies for cGvHD and as assessed for responders only. Response was based on cGvHD disease assessments (National Institutes of Health consensus criteria). Duration of response was evaluated in participants who achieved a CR or PR at or before Cycle 7 Day 1. The analysis included a larger number of participants than the number of participants who achieved CR or PR at Cycle 7 Day 1 (82 ruxolitinib and 42 BAT) because the analysis took into account not only those participants who achieved CR or PR at Cycle 7 Day 1, but also participants who achieved CR or PR before Cycle 7 Day 1 but who may have lost their response at Cycle 7 Day 1. For this reason, the number of participants in this analysis does not align with the best overall response (BOR) at Cycle 7 Day 1. This analysis was based on the cutoff date upon study completion (December 2022).

    Time frame: from first response to LPLV (approximately 5 years)

  8. Overall Survival (OS)

    Overall survival was defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: from the date of randomization to the date of death due to any cause up to LPLV (approximately 5 years)

  9. Cumulative Incidence of Non-relapse Mortality (NRM)

    Defined as the cumulative incidence rate from competing risk analysis for NRM from the date of randomization to the date of death not preceded by underlying disease relapse/recurrence.

    Time frame: Months 3, 6, 12, 18, 24, 30, and 36

  10. Percentage of Participants With a ≥ 50% Reduction in Daily Corticosteroid Dose

    All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants with a ≥ 50% reduction in daily corticosteroid dose.

    Time frame: from Day 15 up to Day 182

  11. Percentage of Participants Successfully Tapered Off of All Corticosteroids

    All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.

    Time frame: up to Day 179

  12. Cumulative Incidence of Malignancy Relapse/Recurrence (MR)

    Defined as the cumulative incidence rate from competing risk analysis of MR from the date of randomization to hematologic malignancy relapse/recurrence.

    Time frame: Months 3, 6, 12, 18, 24, 30, and 36

  13. Change From Baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)

    Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The FACT-BMT is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family, and emotional well-being, together with additional concerns relevant for bone marrow transplantation participants. The questions were based on a 5-point Likert scale, where 0 corresponds to "not at all" and 4 corresponds to "very much." The higher the final score, the better the quality of life. The FACT-BMT total score ranges from 0 to 148.

    Time frame: Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)

  14. Change From Baseline in EQ-5D-5L

    The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.

    Time frame: Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)

  15. Number of Participants With Any Treatment-emergent Adverse Event (TEAE)

    Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occurred after the participant's signed informed consent was obtained. Abnormal laboratory values or test results occurring after informed consent constituted adverse events only if they induced clinical signs or symptoms, were considered clinically significant, required therapy (e.g., hematologic abnormality that required transfusion or hematological stem cell support), or required changes in study medication(s). TEAEs were defined as those AEs that started or worsened during the on-treatment period (either randomized or cross-over period).

    Time frame: from Baseline to LPLV (approximately 5 years)

  16. Cmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    Cmax was defined as the maximum observed plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  17. AUClast of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    AUClast was defined as the area under the concentration-time curve up to the last measurable concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  18. AUCinf of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    AUCinf was defined as the area under the concentration-time curve from time 0 to infinity. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  19. CL/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    CL/F was defined as the oral dose clearance of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  20. Vz/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    Vz/F was defined as the apparent oral dose volume of distribution of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  21. Tmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    tmax was defined as the time to reach the maximum plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  22. t1/2 of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

    t1/2 was defined as the apparent terminal phase disposition half-life of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

    Time frame: Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose

  23. Utilization of Medical Resources

    The percentage of participants with at least one submission to healthcare encounter was assessed.

    Time frame: from Baseline to LPLV (approximately 5 years)

07

Results

Posted Apr 15, 2022

Participant flow

The study was conducted in 29 countries globally. During the main treatment period, participants were randomly assigned to a ruxolitinib arm or a Best Available Therapy (BAT) arm for 6 cycles of treatment. At the end of Cycle 6, participants in the BAT arm either crossed over to ruxolitinib treatment or entered the survival follow-up phase.

End of Randomization Period
Participant flow — End of Randomization Period
MilestoneRuxolitinibBest Available TherapyRuxolitinib Cross-Over Period
Started1651640
Completed29240
Not completed1361400
Withdrew: Lost to follow-up300
Withdrew: Participant/guardian decision7140
Withdrew: Physician decision43180
Withdrew: Failure to meet protocol continuation criteria450
Withdrew: Death1070
Withdrew: Disease relapse1270
Withdrew: Lack of efficacy25770
Withdrew: Adverse event32120
End of Cross Over Period
Participant flow — End of Cross Over Period
MilestoneRuxolitinibBest Available TherapyRuxolitinib Cross-Over Period
Started0070
Completed0016
Not completed0054
Withdrew: Death002
Withdrew: Participant/guardian decision007
Withdrew: Physician decision0029
Withdrew: Lack of efficacy008
Withdrew: Adverse event006
Withdrew: Disease relapse002

Outcome measures

PrimaryEfficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit

ORR was defined as the percentage of participants in each arm demonstrating a complete response (CR) or partial response (PR) based on chronic GvHD (cGvHD) disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

Time frame:
Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Number · percentage of participants
Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit
percentage of participantsRuxolitinibBest Available Therapy
Efficacy of Ruxolitinib Versus Investigator's Choice Best Available Therapy (BAT) in Participants With Moderate or Severe Steroid Refractory Chronic Graft Versus Host Disease (SR-cGvHD) Assessed by Overall Response Rate (ORR) at the Cycle 7 Day 1 Visit49.7 (41.8 to 57.6)25.6 (19.1 to 33.0)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Cochran-Mantel-Haenszel · p = <0.0001 · Odds ratio (or): 2.99 · 95% CI 1.86 to 4.80
SecondaryRate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score

To assess improvement of symptoms based on the total symptom score (TSS); a responder was defined as having achieved a clinically relevant reduction from Baseline of the TSS. The scale consists of 30 items in 7 subscales (skin, eye, mouth, lung, nutrition, energy, and psychological). Participants reported their level of symptom "bother" over the previous month on a 5-point likert scale: not at all, slightly, moderately, quite a bit, or extremely. Subscale scores and the summary score range from 0 to 100, with a higher score indicating worse symptoms.

Time frame:
Baseline; Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Number · percentage of participants
Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score
percentage of participantsRuxolitinibBest Available Therapy
Rate of Participants With Clinically Relevant Improvement of the Modified Lee cGvHD Symptom Scale Score24.2 (17.9 to 31.5)11.0 (6.6 to 16.8)
SecondaryRate of Failure-free Survival (FFS)

Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.

Time frame:
Baseline to when the last participant reached Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Median · months
Rate of Failure-free Survival (FFS)
monthsRuxolitinibBest Available Therapy
Rate of Failure-free Survival (FFS)NA (18.6 to NA)5.7 (5.6 to 6.5)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Log Rank · p = <0.0001 (The p-value was derived from a 1-sided stratified log-rank test.) · Hazard ratio (hr): 0.370 · 95% CI 0.268 to 0.510The hazard ratio was obtained from a stratified Cox model using cGvHD severity at randomization as strata.
SecondaryRate of FFS at Study Completion

Composite time to event endpoint incorporating the following FFS events: (i) relapse or recurrence of underlying disease or death due to underlying disease, (ii) nonrelapse mortality, or (iii) addition or initiation of another systemic therapy for cGvHD.

Time frame:
From Baseline to Last Participant Last Visit (LPLV) (approximately 5 years)
Reported as:
Median · months
Rate of FFS at Study Completion
monthsRuxolitinibBest Available Therapy
Rate of FFS at Study Completion38.4 (22.1 to NA)5.7 (5.6 to 6.5)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Hazard ratio (hr): 0.361 · 95% CI 0.268 to 0.485The hazard ratio was obtained from a stratified Cox model using cGvHD severity at randomization as strata.
SecondaryBest Overall Response (BOR) at Cycle 7 Day 1

BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies. This analysis was based on the primary cutoff date (May 2020).

Time frame:
up to Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Number · percentage of participants
Best Overall Response (BOR) at Cycle 7 Day 1
percentage of participantsRuxolitinibBest Available Therapy
Best Overall Response (BOR) at Cycle 7 Day 176.4 (69.1 to 82.6)60.4 (52.4 to 67.9)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Cochran-Mantel-Haenszel · p = 0.0011 (The one-sided p-value was calculated using a stratified Cochran-Mantel-Haenszel test.) · Odds ratio (or): 2.17 · 95% CI 1.34 to 3.52The odds ratio and 95% confidence interval (CI) were calculated using a stratified Cochran-Mantel-Haenszel test.
SecondaryBOR During Cross-over Treatment With Ruxolitinib

BOR was defined as the percentage of participants who achieved an overall response (CR+PR) based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response at any time point (up to Cycle 7 Day 1 or the start of additional systemic therapy for cGvHD). Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

Time frame:
from Crossover Cycle 1 Day 1 to any time point up to and including Crossover Cycle 7 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Number · percentage of participants
BOR During Cross-over Treatment With Ruxolitinib
percentage of participantsRuxolitinib Cross-Over Period
BOR During Cross-over Treatment With Ruxolitinib81.4 (70.3 to 89.7)
SecondaryORR at the End of Cycle 3

ORR was defined as the percentage of participants in each arm demonstrating a CR or PR based on cGvHD disease assessments (National Institutes of Health Consensus Criteria) without the requirement of additional systemic therapies for an earlier progression, mixed response, or non-response. Scoring of response was relative to the organ score at the time of randomization. CR: complete resolution of all signs and symptoms of cGVHD in all evaluable organs without the initiation or addition of new systemic therapy. PR: improvement in at least one organ (e.g., improvement of 1 or more points on a 4- to 7-point scale, or an improvement of 2 or more points on a 10- to 12-point scale) without progression in other organs or sites, initiation, or addition of new systemic therapies.

Time frame:
Cycle 4 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Number · percentage of participants
ORR at the End of Cycle 3
percentage of participantsRuxolitinibBest Available Therapy
ORR at the End of Cycle 354.5 (46.6 to 62.3)31.1 (24.1 to 38.8)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Cochran-Mantel-Haenszel · p = <0.0001 (The one-sided p-value was calculated using a stratified Cochran-Mantel-Haenszel (CMH) test.) · Odds ratio (or): 2.77 · 95% CI 1.75 to 4.39The odds ratio and 95% CI were calculated using a stratified CMH test.
SecondaryDuration of Response Through Study Completion

DOR was defined as the time from first response until cGvHD progression, death, or the date of change/addition of systemic therapies for cGvHD and as assessed for responders only. Response was based on cGvHD disease assessments (National Institutes of Health consensus criteria). Duration of response was evaluated in participants who achieved a CR or PR at or before Cycle 7 Day 1. The analysis included a larger number of participants than the number of participants who achieved CR or PR at Cycle 7 Day 1 (82 ruxolitinib and 42 BAT) because the analysis took into account not only those participants who achieved CR or PR at Cycle 7 Day 1, but also participants who achieved CR or PR before Cycle 7 Day 1 but who may have lost their response at Cycle 7 Day 1. For this reason, the number of participants in this analysis does not align with the best overall response (BOR) at Cycle 7 Day 1. This analysis was based on the cutoff date upon study completion (December 2022).

Time frame:
from first response to LPLV (approximately 5 years)
Reported as:
Median · Months
Duration of Response Through Study Completion
MonthsRuxolitinibBest Available Therapy
Duration of Response Through Study CompletionNA (NA to NA)6.4 (4.9 to 11.4)
SecondaryOverall Survival (OS)

Overall survival was defined as the time from the date of randomization to the date of death due to any cause.

Time frame:
from the date of randomization to the date of death due to any cause up to LPLV (approximately 5 years)
Reported as:
Median · months
Overall Survival (OS)
monthsRuxolitinibBest Available Therapy
Overall Survival (OS)NA (NA to NA)NA (41.0 to NA)
Statistical analysis
  • Ruxolitinib vs Best Available Therapy · Log Rank · p = 0.2396 (The p-value was derived from a 1-sided stratified log-rank test.) · Hazard ratio (hr): 0.851 · 95% CI 0.544 to 1.331The hazard ratio was obtained from a stratified Cox model using cGvHD severity at randomization as strata.
SecondaryCumulative Incidence of Non-relapse Mortality (NRM)

Defined as the cumulative incidence rate from competing risk analysis for NRM from the date of randomization to the date of death not preceded by underlying disease relapse/recurrence.

Time frame:
Months 3, 6, 12, 18, 24, 30, and 36
Reported as:
Number · percentage of participants
Cumulative Incidence of Non-relapse Mortality (NRM)
percentage of participantsRuxolitinibBest Available Therapy
Month 35.45 (2.68 to 9.67)4.44 (1.96 to 8.48)
Month 69.13 (5.34 to 14.15)6.43 (3.28 to 11.03)
Month 1215.30 (10.26 to 21.26)15.12 (9.94 to 21.30)
Month 1815.93 (10.78 to 21.98)16.48 (11.06 to 22.84)
Month 2417.83 (12.37 to 24.10)19.22 (13.36 to 25.90)
Month 3017.83 (12.37 to 24.10)19.22 (13.94 to 26.67)
Month 3617.83 (12.37 to 24.10)22.0 (15.73 to 28.96)
SecondaryPercentage of Participants With a ≥ 50% Reduction in Daily Corticosteroid Dose

All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants with a ≥ 50% reduction in daily corticosteroid dose.

Time frame:
from Day 15 up to Day 182
Reported as:
Number · percentage of participants
Percentage of Participants With a ≥ 50% Reduction in Daily Corticosteroid Dose
percentage of participantsRuxolitinibBest Available Therapy
Day 15 to ≤ Day 2812.713.2
Day 29 to ≤ Day 4235.033.1
Day 43 to ≤ Day 5648.441.1
Day 57 to ≤ Day 7058.747.9
Day 71 to ≤ Day 8462.351.4
Day 85 to ≤ Day 9869.554.0
Day 99 to ≤ Day 11271.260.4
Day 113 to ≤ Day 12673.266.2
Day 127 to ≤ Day 14072.868.3
Day 141 to ≤ Day 15470.068.3
Day 155 to ≤ Day 16874.671.6
Day 169 to ≤ Day 18281.988.8
SecondaryPercentage of Participants Successfully Tapered Off of All Corticosteroids

All corticosteroid dosages prescribed to the participant and all dose changes during the study were to be recorded for assessment of participants who successfully tapered off of all corticosteroids. Participants who completely tapered off corticosteroids refer to those who permanently discontinued steroids as per the dose administration panel and who did not restart steroids in the same interval. Participants who were tapered off and continued follow-up were also counted as being tapered off with 0 dose in subsequent intervals until they discontinued from the main treatment period or restarted steroid treatment.

Time frame:
up to Day 179
Reported as:
Number · percentage of participants
Percentage of Participants Successfully Tapered Off of All Corticosteroids
percentage of participantsRuxolitinibBest Available Therapy
Day 1 to ≤ Day 282.52.6
Day 29 to ≤ Day 569.65.4
Day 57 to ≤ Day 8414.08.5
Day 85 to ≤ Day 11216.310.3
Day 113 to ≤ Day 14019.712.4
Day 141 to ≤ Day 16824.216.8
Day 169 to ≤ Day 17924.115.9
SecondaryCumulative Incidence of Malignancy Relapse/Recurrence (MR)

Defined as the cumulative incidence rate from competing risk analysis of MR from the date of randomization to hematologic malignancy relapse/recurrence.

Time frame:
Months 3, 6, 12, 18, 24, 30, and 36
Reported as:
Number · percentage of participants
Cumulative Incidence of Malignancy Relapse/Recurrence (MR)
percentage of participantsRuxolitinibBest Available Therapy
0 to < 3 months1.92 (0.52 to 5.12)1.31 (0.26 to 4.27)
3 to < 6 months3.22 (1.20 to 6.93)2.65 (0.87 to 6.21)
6 to < 12 months5.18 (2.42 to 9.49)6.08 (2.98 to 10.73)
12 to < 18 months7.82 (4.25 to 12.77)6.08 (2.98 to 10.73)
18 to < 24 months8.48 (4.74 to 13.57)6.08 (2.98 to 10.73)
24 to <30 months8.48 (4.74 to 13.57)6.78 (3.46 to 11.62)
30 to <36 months8.48 (4.74 to 13.57)7.50 (3.96 to 12.52)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)

Change from Baseline was calculated as the post-Baseline value minus the Baseline value. The FACT-BMT is a 50-item self-report questionnaire that measures the effect of a therapy on domains including physical, functional, social/family, and emotional well-being, together with additional concerns relevant for bone marrow transplantation participants. The questions were based on a 5-point Likert scale, where 0 corresponds to "not at all" and 4 corresponds to "very much." The higher the final score, the better the quality of life. The FACT-BMT total score ranges from 0 to 148.

Time frame:
Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Mean · scores on a scale
Change From Baseline in Functional Assessment of Cancer Therapy - Bone Marrow Transplantation (FACT-BMT)
scores on a scaleRuxolitinibBest Available Therapy
Cycle 2 Day 12.32 ± 12.191-0.22 ± 14.949
Cycle 3 Day 10.62 ± 14.452-1.82 ± 15.849
Cycle 4 Day 11.98 ± 15.888-1.05 ± 16.147
Cycle 5 Day 11.25 ± 14.577-0.23 ± 18.903
Cycle 6 Day 12.91 ± 14.5622.41 ± 14.766
Cycle 7 Day 14.14 ± 14.6690.85 ± 16.811
Cycle 9 Day 15.32 ± 16.8151.20 ± 17.635
Cycle 12 Day 17.26 ± 19.2963.74 ± 18.059
Cycle 15 Day 15.07 ± 18.2207.58 ± 17.063
Cycle 18 Day 14.10 ± 19.4408.19 ± 17.993
Cycle 21 Day 15.24 ± 19.4853.68 ± 17.378
Cycle 24 Day 15.90 ± 19.6627.84 ± 18.561
Cycle 27 Day 16.23 ± 18.8805.10 ± 18.885
Cycle 30 Day 17.53 ± 20.3145.75 ± 21.037
Cycle 33 Day 15.17 ± 20.3305.67 ± 22.573
Cycle 36 Day 18.72 ± 18.7104.77 ± 24.186
Cycle 39 Day 18.65 ± 21.6696.64 ± 22.384
SecondaryChange From Baseline in EQ-5D-5L

The EQ-5D-5L is a descriptive classification consisting of five dimensions of health: mobility, self-care, usual activities, anxiety/depression, and pain/discomfort. The five-level version (no problems, slight problems, moderate problems, severe problems, and extreme problems) uses a 5-point Likert scale, with 1 being no problems and 5 being extreme problems.

Time frame:
Baseline; up to Cycle 39 Day 1 (each cycle was comprised of 4 weeks)
Reported as:
Mean · scores on a scale
Change From Baseline in EQ-5D-5L
scores on a scaleRuxolitinibBest Available Therapy
Cycle 2 Day 10.03 ± 0.214-0.01 ± 0.163
Cycle 3 Day 10.03 ± 0.221-0.04 ± 0.259
Cycle 4 Day 10.04 ± 0.196-0.01 ± 0.192
Cycle 5 Day 10.02 ± 0.210-0.03 ± 0.243
Cycle 6 Day 10.05 ± 0.2300.01 ± 0.186
Cycle 7 Day 10.07 ± 0.234-0.00 ± 0.225
Cycle 9 Day 10.07 ± 0.228-0.02 ± 0.166
Cycle 12 Day 10.07 ± 0.1870.02 ± 0.158
Cycle 15 Day 10.07 ± 0.2500.03 ± 0.140
Cycle 18 Day 10.07 ± 0.2990.02 ± 0.110
Cycle 21 Day 10.08 ± 0.268-0.00 ± 0.222
Cycle 24 Day 10.07 ± 0.2720.01 ± 0.164
Cycle 27 Day 10.06 ± 0.2990.03 ± 0.182
Cycle 30 Day 10.05 ± 0.2610.01 ± 0.159
Cycle 33 Day 10.00 ± 0.2820.05 ± 0.186
Cycle 36 Day 10.06 ± 0.2310.04 ± 0.216
Cycle 39 Day 10.06 ± 0.2550.01 ± 0.214
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE)

Adverse events were defined as the appearance of (or worsening of any pre-existing) undesirable signs, symptoms, or medical conditions that occurred after the participant's signed informed consent was obtained. Abnormal laboratory values or test results occurring after informed consent constituted adverse events only if they induced clinical signs or symptoms, were considered clinically significant, required therapy (e.g., hematologic abnormality that required transfusion or hematological stem cell support), or required changes in study medication(s). TEAEs were defined as those AEs that started or worsened during the on-treatment period (either randomized or cross-over period).

Time frame:
from Baseline to LPLV (approximately 5 years)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)
ParticipantsRuxolitinibBest Available TherapyRuxolitinib Cross-Over Period
Number of Participants With Any Treatment-emergent Adverse Event (TEAE)16514870
SecondaryCmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

Cmax was defined as the maximum observed plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Cmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
nanograms per milliliter (ng/mL)Ruxolitinib
Day 1167 ± 39.3
Day 15215 ± 48.8
SecondaryAUClast of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

AUClast was defined as the area under the concentration-time curve up to the last measurable concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · ng*hour/mL
AUClast of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
ng*hour/mLRuxolitinib
Day 1636 ± 40.8
Day 15945 ± 56.1
SecondaryAUCinf of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

AUCinf was defined as the area under the concentration-time curve from time 0 to infinity. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · ng*hour/mL
AUCinf of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
ng*hour/mLRuxolitinib
Day 1642 ± 32.7
SecondaryCL/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

CL/F was defined as the oral dose clearance of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · Liters/hour
CL/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
Liters/hourRuxolitinib
Day 115.6 ± 32.7
Day 1515.2 ± 20.4
SecondaryVz/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

Vz/F was defined as the apparent oral dose volume of distribution of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · Liters
Vz/F of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
LitersRuxolitinib
Day 154.0 ± 25.0
Day 1550.9 ± 33.9
SecondaryTmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

tmax was defined as the time to reach the maximum plasma concentration of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Median · hours
Tmax of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
hoursRuxolitinib
Day 10.833 (0.417 to 4.08)
Day 151.00 (0.417 to 2.00)
Secondaryt1/2 of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses

t1/2 was defined as the apparent terminal phase disposition half-life of ruxolitinib. Early enrolling participants (approximately the first 8 adult and first 4 adolescent participants) randomized to ruxolitinib arm followed an "extensive PK" sampling schedule. Subsequent participants randomized to ruxolitinib, any randomized participants receiving ruxolitinib after Cycle 6, and any randomized participants receiving BAT that cross over to ruxolitinib followed the "sparse PK" sampling schedule.

Time frame:
Extensive Sampling Schedule: Cycle 1 Days 1 and 15: predose; 0.5, 1, 1.5, 4, 6, and 9 hours post-dose. Sparse Sampling Schedule: Cycle 1 Days 1 and 15: predose; 1.5 hours post-dose
Reported as:
Geometric mean · hours
t1/2 of Ruxolitinib After Single (Cycle 1 Day 1) and Multiple (Cycle 1 Day 15) Doses
hoursRuxolitinib
Day 12.40 ± 28.9
Day 152.32 ± 19.8
SecondaryUtilization of Medical Resources

The percentage of participants with at least one submission to healthcare encounter was assessed.

Time frame:
from Baseline to LPLV (approximately 5 years)
Reported as:
Number · percentage of participants
Utilization of Medical Resources
percentage of participantsRuxolitinibBest Available Therapy
Utilization of Medical Resources57.065.8

Adverse events

Collected over from Baseline to LPLV (approximately 5 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ruxolitinib37/165 (22.4%)86/165 (52.1%)158/165 (95.8%)
Best Available Therapy40/158 (25.3%)71/158 (44.9%)132/158 (83.5%)
Ruxolitinib Cross-Over Period10/70 (14.3%)27/70 (38.6%)62/70 (88.6%)
Most frequent serious events
Showing 10 of 220
Most frequent serious events
EventRuxolitinibBest Available TherapyRuxolitinib Cross-Over Period
PneumoniaInfections and infestations24/16518/1585/70
PyrexiaGeneral disorders11/1657/1583/70
AnaemiaBlood and lymphatic system disorders1/1650/1583/70
Respiratory tract infectionInfections and infestations2/1650/1583/70
Lower respiratory tract infectionInfections and infestations5/1651/1581/70
Ulcerative keratitisEye disorders0/1650/1582/70
Upper respiratory tract infectionInfections and infestations1/1652/1582/70
DyspnoeaRespiratory, thoracic and mediastinal disorders3/1653/1582/70
Bronchopulmonary aspergillosisInfections and infestations3/1654/1580/70
Septic shockInfections and infestations2/1654/1581/70
Most frequent other events
Showing 10 of 57
Most frequent other events
EventRuxolitinibBest Available TherapyRuxolitinib Cross-Over Period
AnaemiaBlood and lymphatic system disorders56/16525/15815/70
PyrexiaGeneral disorders34/16516/1589/70
HypertensionVascular disorders33/16521/1587/70
Alanine aminotransferase increasedInvestigations32/1658/1585/70
Blood creatinine increasedInvestigations29/1658/1584/70
Upper respiratory tract infectionInfections and infestations19/16515/15812/70
CoughRespiratory, thoracic and mediastinal disorders25/16515/15812/70
DiarrhoeaGastrointestinal disorders27/16523/1586/70
NeutropeniaBlood and lymphatic system disorders25/1658/1588/70
FatigueGeneral disorders25/16515/1587/70

Baseline characteristics

Age, Continuous
Age, Continuous(Years)RuxolitinibBest Available TherapyTotal
Mean45.9 ± 15.6847.2 ± 16.1746.5 ± 15.92
Sex: Female, Male
Sex: Female, Male(Participants)RuxolitinibBest Available TherapyTotal
Female5672128
Male10992201
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RuxolitinibBest Available TherapyTotal
White116132248
Black or African American202
Asian332154
American Indian or Alaska Native202
Other9413
Unknown3710
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RuxolitinibBest Available TherapyTotal
Hispanic/Latino131326
Not Hispanic/Latino118115233
Not Reported262551
Unknown81119
ECOG Performance Status
ECOG Performance Status(Participants)RuxolitinibBest Available TherapyTotal
0394281
19282174
2222244
3022
Missing121628
08

Study locations

191 sites
  • Incyte Investigative Site
    Tucson, Arizona 85724, United States
  • Incyte Investigative Site
    Duarte, California 31010, United States
  • Incyte Investigative Site
    La Jolla, California 92093-0987, United States
  • Incyte Investigative Site
    Los Angeles, California 90033, United States
  • Incyte Investigative Site
    New Haven, Connecticut 06510, United States
  • Incyte Investigative Site
    Wilmington, Delaware 19803, United States
  • Incyte Investigative Site
    Gainesville, Florida 32610, United States
  • Incyte Investigative Site
    Tampa, Florida 33612, United States
  • Incyte Investigative Site
    Chicago, Illinois 60611, United States
  • Incyte Investigative Site
    Chicago, Illinois 60612, United States
  • Incyte Investigative Site
    Chicago, Illinois 60637, United States
  • Incyte Investigative Site
    Maywood, Illinois 60153, United States
  • Incyte Investigative Site
    Indianapolis, Indiana 46237, United States
  • Incyte Investigative Site
    Westwood, Kansas 66205, United States
  • Incyte Investigative Site
    Lexington, Kentucky 40536, United States
  • Incyte Investigative Site
    Boston, Massachusetts 02114, United States
  • Incyte Investigative Site
    Boston, Massachusetts 02215, United States
  • Incyte Investigative Site
    Omaha, Nebraska 68198-7680, United States
  • Incyte Investigative Site
    Hackensack, New Jersey 07601, United States
  • Incyte Investigative Site
    New York, New York 10021, United States
  • Incyte Investigative Site
    New York, New York 10032, United States
  • Incyte Investigative Site
    New York, New York 11040, United States
  • Incyte Investigative Site
    Chapel Hill, North Carolina 27599, United States
  • Incyte Investigative Site
    Durham, North Carolina 27710, United States
  • Incyte Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Incyte Investigative Site
    Cincinnati, Ohio 45242, United States
  • Incyte Investigative Site
    Cleveland, Ohio 44106-5048, United States
  • Incyte Investigative Site
    Cleveland, Ohio 44195, United States
  • Incyte Investigative Site
    Columbus, Ohio 43210, United States
  • Incyte Investigative Site
    Oklahoma City, Oklahoma 73104, United States
  • Incyte Investigative Site
    Philadelphia, Pennsylvania 19104, United States
  • Incyte Investigative Site
    Pittsburgh, Pennsylvania 15224, United States
  • Incyte Investigative Site
    Pittsburgh, Pennsylvania 15232, United States
  • Incyte Investigative Site
    Nashville, Tennessee 37232, United States
  • Incyte Investigative Site
    Dallas, Texas 75390, United States
  • Incyte Investigative Site
    Houston, Texas 77030, United States
  • Incyte Investigative Site
    Seattle, Washington 98109, United States
  • Incyte Investigative Site
    Milwaukee, Wisconsin 53226, United States
  • Novartis Investigative Site
    Darlinghurst, New South Wales 2010, Australia
  • Novartis Investigative Site
    Parkville, Victoria 3002, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Linz, A-4010, Austria
  • Novartis Investigative Site
    Vienna, A-1090, Austria
  • Novartis Investigative Site
    Antwerp, 2060, Belgium
  • Novartis Investigative Site
    Bruges, 8000, Belgium
  • Novartis Investigative Site
    Brussels, 1200, Belgium
  • Novartis Investigative Site
    Ghent, 9000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Liège, 4000, Belgium
  • Novartis Investigative Site
    Sofia, 1527, Bulgaria
  • Novartis Investigative Site
    Sofia, 1756, Bulgaria
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8V 5C2, Canada
  • Novartis Investigative Site
    Ottawa, Ontario K1H 8L6, Canada
  • Novartis Investigative Site
    Toronto, Ontario M5G 2M9, Canada
  • Novartis Investigative Site
    Prague, Czech Republic 128 20, Czechia
  • Novartis Investigative Site
    Hradec Králové, CZE 500 05, Czechia
  • Novartis Investigative Site
    Prague, 150 06, Czechia
  • Novartis Investigative Site
    Copenhagen, DK-2100, Denmark
  • Novartis Investigative Site
    Odense, DK 5000, Denmark
  • Novartis Investigative Site
    Bordeaux, Aquitaine 33076, France
  • Novartis Investigative Site
    Amiens Cedex1, 80054, France
  • Novartis Investigative Site
    Caen, 14033, France
  • Novartis Investigative Site
    Lille, 59037, France
  • Novartis Investigative Site
    Limoges, 87042, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Montpellier, 34295, France
  • Novartis Investigative Site
    Paris, 75475, France
  • Novartis Investigative Site
    Paris, 75571, France
  • Novartis Investigative Site
    Paris, 75935, France
  • Novartis Investigative Site
    Pierre-Benite Cédex, 69495, France
  • Novartis Investigative Site
    Rennes, 35033, France
  • Novartis Investigative Site
    Rouen, 76038, France
  • Novartis Investigative Site
    Saint-Priest-en-Jarez, 42271, France
  • Novartis Investigative Site
    Strasbourg, 67098, France
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Vandœuvre-lès-Nancy, 54511, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68167, Germany
  • Novartis Investigative Site
    Augsburg, 86156, Germany
  • Novartis Investigative Site
    Berlin, 13125, Germany
  • Novartis Investigative Site
    Cologne, 50937, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Düsseldorf, 40225, Germany
  • Novartis Investigative Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 45147, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Freiburg im Breisgau, 79106, Germany
  • Novartis Investigative Site
    Hamburg, 20099, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Jena, 07747, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Mainz, 55131, Germany
  • Novartis Investigative Site
    Mannheim, 68167, Germany
  • Novartis Investigative Site
    Münster, 48149, Germany
  • Novartis Investigative Site
    Ulm, Germany
  • Novartis Investigative Site
    Würzburg, 97080, Germany
  • Novartis Investigative Site
    Athens, GR, Greece
  • Novartis Investigative Site
    Pátrai, GR 265 00, Greece

Showing the first 100 of 191 sites across 31 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Mahmoudjafari Z, Bhatt V, Xue Z, Locatelli F, Socie G, Zeiser R. Clinical considerations for ruxolitinib in the treatment of steroid-refractory acute graft-versus-host disease (GVHD) and steroid-refractory or -dependent chronic GVHD: a plain language summary. Ther Adv Hematol. 2026 May 19;17:20406207261442908. doi: 10.1177/20406207261442908. eCollection 2026. PubMed 42180389 ↗
  • Zeiser R, Russo D, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hamad N, Burock K, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F. Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study. J Clin Oncol. 2025 Aug 10;43(23):2566-2571. doi: 10.1200/JCO-24-02477. Epub 2025 Jun 25. PubMed 40561385 ↗
  • Mahmoudjafari Z, Kintsch E, Xue Z, Bhatt V, Galvin J, Locatelli F, Zeiser R. Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3. Blood Adv. 2025 Aug 26;9(16):4206-4216. doi: 10.1182/bloodadvances.2025016212. PubMed 40472328 ↗
  • Le RQ, Wang X, Zhang H, Li H, Przepiorka D, Vallejo J, Leong R, Ma L, Goldberg KB, Pazdur R, Theoret MR, De Claro A. FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy. Oncologist. 2022 Jun 8;27(6):493-500. doi: 10.1093/oncolo/oyac042. PubMed 35363318 ↗
  • Zeiser R, Polverelli N, Ram R, Hashmi SK, Chakraverty R, Middeke JM, Musso M, Giebel S, Uzay A, Langmuir P, Hollaender N, Gowda M, Stefanelli T, Lee SJ, Teshima T, Locatelli F; REACH3 Investigators. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. N Engl J Med. 2021 Jul 15;385(3):228-238. doi: 10.1056/NEJMoa2033122. PubMed 34260836 ↗
  • Jagasia M, Zeiser R, Arbushites M, Delaite P, Gadbaw B, Bubnoff NV. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH trials. Immunotherapy. 2018 Apr;10(5):391-402. doi: 10.2217/imt-2017-0156. Epub 2018 Jan 10. PubMed 29316837 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in May 2020, 34 months.

Results were first posted in Apr 2022, 1 year 11 months after primary completion. A results delay was requested in May 2021.

Of 31 phase 3 interventional studies under Graft vs Host Disease, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 48. This study's 34 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2017
First posted
Apr 13, 2017
StartActual
Jun 29, 2017
Primary completionActual
May 8, 2020
CompletionActual
Dec 15, 2022
Results delay requested
May 4, 2021
Results first posted
Apr 15, 2022
Last update
Aug 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03112603
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Apr 13, 2017
Start date
Jun 29, 2017
Primary completion
May 8, 2020
Completion
Dec 15, 2022
Results posted
Apr 15, 2022
Last update
Aug 12, 2025

Study contacts

Rodica Morariu-Zamfir
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion